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Abstract
Background: Metabolites of arachidonic acid such as prostacyclin (PGI2) have been shown to participate in the
pathogenesis of pulmonary fibrosis by inhibiting the expression of pro-inflammatory and pro-fibrotic mediators. In
this investigation, we examined whether iloprost, a stable PGI2 analogue, could prevent bleomycin-induced
pulmonary inflammation and fibrosis in a mouse model.
Methods: Mice received a single intratracheal injection of bleomycin with or without intraperitoneal iloprost.
Pulmonary inflammation and fibrosis were analysed by histological evaluation, cellular composition of
bronchoalveolar lavage (BAL) fluid, and hydroxyproline content. Lung mechanics were measured. We also analysed
the expression of inflammatory mediators in BAL fluid and lung tissue.
Results: Administration of iloprost significantly improved survival rate and reduced weight loss in the mice
induced by bleomycin. The severe inflammatory response and fibrotic changes were significantly attenuated in the
mice treated with iloprost as shown by reduction in infiltration of inflammatory cells into the airways and
pulmonary parenchyma, diminution in interstitial collagen deposition, and lung hydroxyproline content. Iloprost
significantly improved lung static compliance and tissue elastance. It increased the expression of IFNg and CXCL10
in lung tissue measured by RT-PCR and their levels in BAL fluid as measured by ELISA. Levels of TNFa, IL-6 and
TGFb1 were lowered by iloprost.
Conclusions: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic
mediators (IFNg and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFa, IL-6, and
TGFb1). Prostacyclin may represent a novel pharmacological agent for treating pulmonary fibrotic diseases.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressively
fatal disorder characterized by inflammatory alveolitis
and scarring in the pulmonary interstitium with loss of
lung function; it is estimated that there is a 70% mortal-
ity within 5 years from initial diagnosis [1]. The current
pharmacologic therapy for IPF is limited and there are
no effective treatments [1]. The mechanisms underlying
the pathogenesis of IPF include the accumulation of
inflammatory cells in the lungs, and the generation of
pro-inflammatory and pro-fibrotic mediators, resulting
in alveolar epithelial cell injury and fibroblast
hyperplasia, and eventually excessive deposition of extra-
cellular collagen [2]. Searching for new agents to meet
this unmet medical need is a priority.
There is accumulating evidence that bioactive metabo-
lites of arachidoic acid (eicosanoids) may either contri-
bute to or protect against lung fibrosis. Eicosanoids may
regulate the fibroproliferative response directly through
an action on lung resident cells and/or indirectly
through modulating recruitment of inflammatory cells,
release of mediators, and intracellular signaling pathways
[3]. Leukotriene (LT) B4, a metabolite synthesized by 5-
lipoxygenase (5-LO), was elevated in bronchoalveolar
(BAL) fluid of patients with IPF [4] and deletion of
5-LO leading to a deficiency in sulphidopeptide-leuko-
triene production ameliorated bleomycin-induced fibro-
sis in mice [5]. In addition, antagonizing LTB4 receptor
attenuated the lung fibrosis induced by bleomycin in
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fibrotic cytokines and by promoting the antifibrotic
cytokine, IFNg [6].
In contrast to LTB4, prostaglandin (PG) E2 generated
by cyclooxygenase (COX)-2 pathway inhibited lung
fibrosis by suppressing fibroblast proliferation and col-
lagen synthesis [7]. The preventive and therapeutic
effects of the administration of a PGE2 synthetic com-
pound on lung fibrosis induced by bleomycin through
anti-inflammatory mechanisms has been recently
demonstrated [8].
PGI2, known as prostacyclin, is produced through the
action of COX-2 and a membrane-anchored prostacy-
clin synthase and is secreted by alveolar type II cells in
large quantities [9]. By specifically binding to a single G-
protein coupled receptor (IP), PGI2 induces anti-inflam-
matory and anti-fibroproliferative activity through ele-
vating intracellular cyclic adenosine monophosphate
(cAMP) [9]. A decreased level of PGI2 was found in
fibroblasts isolated from IPF patients [10]. PGI2 has
been shown to inhibit migration, proliferation and col-
lagen synthesis of fibroblasts in vitro[11,12]. Mice lack-
ing COX-2-derived PGI2 or IP were more susceptible to
developing severe pulmonaryf i b r o s i si nr e s p o n s et o
bleomycin than wild type mice in a PGE2-independent
fashion [13]. Additionally, a synthetic prostacyclin ago-
nist attenuated bleomycin-induced lung fibrosis in mice
[14]. Besides, inhalation of a stable PGI2 analogue, ilo-
prost, was shown to abrogate the allergic inflammation
in animal model of asthma [15].
PGI2 may inhibit the development of lung fibrosis by
controlling inflammation and fibrosis [9]. The aim of
this study was to investigate the role of PGI2 by using
intraperitoneal administration of iloprost in a mouse
model of bleomycin-induced pulmonary fibrosis and the
possible mechanism(s) by which PGI2 might mediate its
effect.
Materials and methods
Mice and bleomycin injection
Mice with C57BL/6 background (6 to 8-week old; 20-25
g body weight) were maintained in a pathogen-free
mouse facility. All experiments were performed accord-
ing to international and institutional guidelines for ani-
mal care and were approved by the Animal Ethics
Committee of Peking Union Medical College Hospital.
Clean food and water were supplied with free access.
The adult male mice were anesthetized with pentobar-
bital intraperitoneally, followed by a single intratracheal
injection of 3 mg/kg of bleomycin sulfate (Nippon
Kayaku, Japan) in 50 μl of sterile phosphate-buffered sal-
ine (PBS). Control mice were injected with 50 μl of ster-
ile PBS. In some experiments examining lung mechanics
and cellular and biochemical characterization of BAL
fluid, we used a smaller dose of bleomycin (2 mg/kg
body weight) in order to avoid significant mortality.
Iloprost (200 μg/kg; Schering, Berlimed, Spain) dis-
solved in 500 μl of PBS was intraperitoneally adminis-
tered 10-15 minutes prior to intratracheal injection of
bleomycin. In some experiments, iloprost was given
intraperitoneally 7 days after bleomycin treatment. The
dosage of iloprost adopted in this investigation was opti-
mized based on the series of preliminary studies, in
which we found no effectiveness at the lower doses of
iloprost of 100 and 150 μg/kg.
The mice were randomly allocated into four groups: 1.
PBS (PBS) alone; 2. PBS+iloprost; 3. bleomycin; 4. bleo-
mycin (Bleo)+iloprost.
Histopathological evaluation of pulmonary fibrosis
On day 14 post-administration, animals were sacrificed
by overdosage of pentobarbital and perfused via the left
ventricle with 5 ml of cold saline. The lungs were care-
fully removed, inflated to 25 cmH2O with 10% formalin
and fixed overnight, embedded in paraffin, and sec-
tioned at 5 μM thickness. The sections were stained
with Hematoxylin & Eosin for routine histology or with
Masson trichrome for mature collagen.
Histopathological scoring of pulmonary fibrosis was
performed as described by Ashcroft and co-workers
[16]. The severity of fibrotic changes in each lung sec-
tion was assessed as a mean score of severity. At least
10 high-power fields within each lung section were
evaluated.
Alveolar septal thickening was quantified using digital
imaging as previously described [17]. Briefly, at least five
images of representative areas of each lung lobe stained
with hematoxylin and eosin were randomly captured
and analyzed for alveolar thickening, accumulation of
leukocytes, and increased extracellular matrix and fibro-
blasts. With NanoZoomer Digital Pathology C9600
(Hamamatsu Photonics K.K., Japan), threshold was
defined as the areas containing thickened septum of
digital images which were automatically counted by the
system. Then the threshold areas were divided by the
total areas of the selected images and multiplied by 100
to generate a percentage of the thickened area in each
mouse.
The pathological analysis was independently per-
formed for each mouse in a blind manner by two
experienced pathologists.
Assessment of lung mechanics
On day 21 after treatment, mice were prepared as pre-
viously described for invasive analysis of lung mechanics
using a computer-controlled small animal ventilator, the
Flexivent system (Scireq, Montreal, PQ, Canada)
[13,18,19]. Briefly, mice were mechanically ventilated at
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a positive end-expiratory pressure of 3 cmH2O. We
documented the tracheal pressure (Ptr), volume (V), and
airflow. Pressure-volume curves were generated after
delivering incremental air into lungs from functional
residual to total lung capacity. Static compliance (Cst),
reflecting elastic recoil of the lungs, was calculated by
the Flexivent software using Salazar-Knowles equation.
Tissue elastance (H) was measured by forced oscillation
technique using Flexivent software.
Bronchoalveolar lavage fluid
Bronchoalveolar lavage (BAL) fluid was conducted as
previously described [20]. Briefly, mice were sacrificed
14 days later, and the trachea was cannulated by using
20-gauge catheter. BAL was performed three times with
0.8 ml of ice-cold PBS (PH 7.4) with 90% of recovery
rate. The BAL fluid was spun, supernatant was collected
and kept at -70°C until used. Recovered total cells were
counted on a hemocytometer in the presence of 0.4%
trypan blue (Sigma, MO). For differential cell counting,
cells were spun onto glass slides, air-dried, fixed, and
routinely stained. The number of macrophages, neutro-
phils and lymphocytes in 200 cells was counted based
on morphology.
Hydroxyproline assay
Total lung collagen was determined by analysis of
hydroxyproline as previously described [21]. Briefly,
lungs were harvested 14 days after treatment and homo-
genized in PBS (PH 7.4), digested with 12N HCl at 120°
C overnight. Citrate/acetate buffer (PH 6.0) and chlora-
mine-T solution were added at room temperature for 20
minutes and the samples were incubated with Ehrlich’s
solution for 15 min at 65°C. Samples were cooled to
room temperature and read at 550 nm. Hydroxyproline
standards (Sigma, MO) at concentrations between 0 to
100 μg/ml were used to construct a standard curve.
RT-PCR analysis for mRNA expression of cytokines
andchemokines
Total RNA was extracted from the lung using TRIzol
reagent (Invitrogen, CA) according to manufacturer’s
instructions, and treated with RNase-free DNase. RNA
was reverse-transcribed into cDNA using M-MuLV
reverse transcriptase (Invitrogen). Then 1 μlo fc D N A
was subjected to PCR in a 25 μl final reaction volume
for analysing the expression of CXCL10/IP-10, IL-6,
TGFb 1, and TNFa. b-actin was analysed as an internal
control. The amplification conditions were as follows:
initial step at 95°C for 10 min, followed by 35 cycles of
95°C for 1 min, 55°C for 1 min and 72°C for 1 min.
The primers and products of RT-PCR are presented in
Table 1.
Analysis of cytokines, chemokines, and eicosanoids
in BALF
The concentrations of IFNg, IL-6, TGFb1, and CXCL10/
IP-10 in BAL fluid were determined by ELISA. The
ELISA kits for IFNg and CXCL10/IP-10 were purchased
f r o mR & Ds y s t e m s ,t h ek i t sf o rI L - 6a n dT G F b1w e r e
products of Amersham Bioscience. The detection limits
of IFNg, IL-6, TGFb1, and CXCL10/IP-10 were 4, 4, 60,
and 2.2 pg/ml, respectively.
The levels of LTB4 and PGE2 were quantified using
enzyme immunoassay (EIA) kits (Cayman chemical,
MI). The detection limits for LTB4 and PGE2 were 15.3
pg/ml and 15.5 pg/ml, respectively.
Statistics
Data are expressed as means ± SEM. Comparisons were
carried out using ANOVA followed by unpaired Stu-
dent’s t test. Survival curves (Kaplan-Meier plots) were
compared using a log rank test (Graph Pad Software
Inc., San Diego, CA). A value of P less than 0.05 was
considered significant.
Results
Effect of iloprost on survival rate and body weight loss
To demonstrate the protective effect of PGI2 on bleomy-
cin-induced pulmonary injury, the mice were intraperito-
neally administered with or without iloprost prior to
injection of bleomycin at a dose of 3 mg/kg. The mice
treated with bleomycin (but not receiving iloprost) began
to die at day 9. Cumulative mortality was 60% at day 21;
by contrast, mortality of mice treated with bleomycin
+iloprost was significantly lower (10% at day 21, P <
0.0001) (Figure 1A). A protective effect of iloprost was
also observed on weight loss. The mice treated with bleo-
mycin (but not receiving iloprost) lost more weight than
the mice treated with bleomycin+iloprost (Figure 1B).
Effect of iloprost on bleomycin-induced pulmonary
inflammation and fibrosis
The effect of iloprost against bleomycin-induced fibrosis
and inflammation was examined. Animals were
Table 1 RT-PCR primers and products
Genes S/AS Primer sequence (5’ to 3’) Products (bp)
CXCL10 S
AS
GTCATTTTCTGCCTCATCC
GAGCCCTTTTAGACCTTTT
273
IL-6 S
AS
TGGGACTGATGCTGGTGA
CTGGCTTTGTCTTTCTTGTTATC
376
TGFb1 S
AS
CCCTGTATTCCGTCTCCTT
GCGGTGCTCGCTTTGTA
363
TNFa S
AS
GGCGGTGCCTATGTCTC
GCAGCCTTGTCCCTTGA
383
b-actin S
AS
CTTCCTTAATGTCACGCACGATTTC
GTGGGGCGGCCCAGGCACCA
541
S, sense; AS, antisense
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Page 3 of 12sacrificed at day 14 after treatment and the lung sec-
tions were analyzed for the severity of inflammation and
fibrosis. As shown in Figure 2, normal alveolar structure
was seen in PBS-treated mice and PBS+iloprost-treated
mice (A and B). Figure 2 shows representative lung his-
tology at day 14 post-bleomycin installation. Mice trea-
ted with bleomycin (no iloprost) had more severe and
extensive inflammation and fibrosis and more obvious
alveolar wall thickening, distorted pulmonary architec-
ture, massive infiltration of leukocytes and excessive
deposition of mature collagen in interstitium (C and E),
compared with the mice administered with bleomycin
+iloprost (D and F).
We measured the thickened areas of alveolar septum
relative to the total area of lung by digital imaging in at
least five photographs of the lower lobes of lungs of the
mice at day 14 post-treatment. PBS- or iloprost+PBS-
treated mice had normal alveolar septa, and all scored
less than 1%. The area of lungs with thickened alveolar
septa treated with bleomycin (no iloprost) was 2.5-fold
greater than in the mice treated with iloprost+bleomycin
(56.1 ± 4.1% vs 23.0 ± 4.9%, P = 0.0004) (Figure 3A).
There were significantly higher histopathologic scores in
the mice treated with bleomycin (no iloprost) than in
the mice treated with iloprost+bleomycin (5.64 ± 0.18 vs
3.35 ± 0.54, P < 0.0001) (Figure 3B).
To quantitatively assess the difference in extent of
pulmonary fibrosis in the bleomycin-treated mice with
or without iloprost, we assayed the hydroxyproline con-
tent unique to mature collagen in the lung tissue. The
amount of hydroxyproline was significantly greater in
bleomycin-treated mice than in iloprost+bleomycin trea-
ted-mice (90.29 ± 6.25 vs 67.84 ± 1.88 μg/left lung, P =
0.02) (Figure 3C).
Effect of iloprost on infiltration of the inflammatory cells
in airways
To determine whether iloprost affects bleomycin-
induced infiltration of inflammatory cells into the air-
ways, we estimated the cell populations in BAL fluid dif-
ferentially 3, 7, and 14 days after bleomycin treatment.
At day 7, the number of total inflammatory cells in BAL
fluid was significantly less in the mice administrated
with iloprost+bleomycin than those treated with bleo-
mycin (no iloprost) (102.4 ± 14.9 × 10
4 vs 194.8 ± 9.0 ×
10
4, P < 0.01) (Figure 4A). At day 14, the total cells
were marginally fewer in the mice treated with iloprost
+bleomycin than those treated with bleomycin (no ilo-
prost) (60.5 ± 6.2 × 10
4 vs 132.0 ± 30.7 × 10
4, P = 0.06).
As represented in Figure 4A, the peak cellular
response occurred at day 7 after bleomycin injection.
The predominant cell type was the lymphocyte and the
number of lymphocytes, not neutrophils and macro-
phages, was significantly greater in the mice treated with
b l e o m y c i n( n oi l o p r o s t )t h a ni nt h o s et r e a t e di l o p r o s t
+bleomycin (143.2 ± 14.3 × 10
4 vs 69.0 ± 12.5 × 10
4;P
< 0.01) (Figure 4B-C).
Effect of iloprost on alteration of lung mechanics
We measured static compliance and tissue elastance in
accordance with the previous studies showing a decrease
in static compliance (Cst) andi n c r e a s ei nt i s s u ee l a -
stance (H) in mice following bleomycin injury [13]. We
found significant alterations of lung mechanics in mice
treated with bleomycin (no iloprost), compared to con-
trol mice treated with PBS (no iloprost). However,
decrease in Cst and increase in H were significantly
attenuated in the mice treated with bleomycin+iloprost
(for Cst: 0.014 ± 0.002 ml/cmH2O vs 0.020 ± 0.001 ml/
cmH2O, P = 0.01; for H: 86.84 ± 13.11 ml/cmH2Ov s
49.96 ± 1.83 ml/cmH2O, P < 0.01) (Figure 5A and 5B).
Effect of iloprost on cytokines, chemokines and
arachidonicacid products
The level of TNFa mRNA was significantly lower in the
mice treated with bleomycin+iloprost than the mice
treated with bleomycin (no iloprost) (Figure 6A). IL-6
Figure 1 Effect of iloprost on survival rate and body weight
loss. Mice were intratracheally injected with 3 mg/kg of bleomycin
(Bleo) (no iloprost) or Bleo+iloprost (200 μg/kg). In the mice treated
with Bleo (no iloprost), the mortality was as high as 60% by day 21;
by contrast, the mortality was only 10% in the mice treated with
Bleo+iloprost (A). Body weight loss was significantly attenuated in
the mice treated with Bleo+iloprost in comparison with those
treated with Bleo (no iloprost) (B). Results are expressed as mean ±
SEM, n = 20 mice per group, *, p < 0.05, ***, p < 0.0001.
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Page 4 of 12mRNA expression was decreased at day 3 and signifi-
cantly lowered by day 7 in the mice treated with ilo-
prost+bleomycin (Figure 6B), while TGFb1m R N Aw a s
significantly inhibited at day 14 (Figure 6C). CXCL10/
IP-10 mRNA was significantly increased in lungs of the
iloprost+bleomycin-treated mice by day 7 (P = 0.03 for
day 3; P = 0.02 for day 7), and remained elevated at day
14 (Figure 6D).
ELISA assays determined that the level of IL-6 pro-
tein in BAL fluid was markedly elevated 3 days after
bleomycin administration (no iloprost), but was signifi-
cantly lower in mice treated with bleomycin+iloprost
(131.5 ± 38.2 pg/ml vs 26.5 ± 4.0 pg/ml, P = 0.02)
(Figure 6E). The concentration of IFNg in BAL fluid
was significantly higher at day 3 and remained elevated
a td a y7i nt h em i c et r e a t e dw i th bleomycin+iloprost,
compared with the mice treated with bleomycin (no
iloprost) (at day 3: 59.3 pg/ml ± 10.5 pg/ml vs 18.9 ±
9.8 pg/ml, P = 0.02; at day 7: 41.0 ± 8.8 pg/ml vs 21.7
± 2.5 pg/ml, P = 0.06) (Figure 6F). The concentration
of TGFb1 was significantly higher in BAL fluid recov-
ered from the mice treated with bleomycin (no ilo-
prost) than from the mice treated with iloprost
+bleomycin at day14 (14350 ± 4798 pg/ml vs 1906 ±
990 pg/ml, P < 0.01) (Figure 6G). The concentration of
IFNg-inducible CXCL10 in BAL fluid was markedly
higher in the mice treated with bleomycin+iloprost
than those treated with bleomycin (no iloprost) at
day 14 (108.4 ± 5.5 vs 65.9 ± 6.4 pg/ml, P = 0.001)
(Figure 6H).
Figure 2 Effect of iloprost on bleomycin-induced pulmonary inflammation and fibrosis. Histological analysis of lungs in the mice treated
with bleomycin and those treated with bleomycin+iloprost. Mice were killed at day 14, lungs were removed, inflated with 1 ml of 10% formalin.
In the mice treated with PBS (no iloprost) or PBS+iloprost, there was normal alveolar structure (A and B). In the mice treated with bleomycin (no
iloprost), there was more accumulation of leukocytes, distortion of alveolar architecture, and deposition of collagen (C and E), compared with the
mice treated with bleomycin+iloprost (D and F). Panels A-D, H&E staining; Panel E-F, Masson’s trichrome staining.
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icantly higher in the mice treated with bleomycin com-
pared with those treated with PBS. However, we found
that LTB4 and PGE2 levels did not differ between the
mice treated with bleomycin (no iloprost) and those
treated with bleomycin+iloprost (Figure 7A and 7B).
Effect of delayed application of iloprost on bleomycin-
induced injury
When iloprost was given at day 7 post-bleomycin insult,
we found that iloprost did not prolong the survival rate,
did not improve the body weight loss, did not alleviate
infiltration of the inflammatory cells, and did not
decrease interstitial collagen accumulation in mice by
day 21 post-bleomycin injection.
Discussion
To our knowledge, this is the first report of an intraperi-
toneal application of iloprost, a PGI2 analogue, that pre-
vented the pulmonary inflammation and fibrosis induced
by bleomycin in mice. A single dose of iloprost prior to
bleomycin injection significantly resulted in: (i) reduced
mortality and body weight loss; (ii) attenuated infiltration
of inflammatory cells into the lung and reduced collagen
deposition in pulmonary interstitium; (iii) alleviation of
the reduced static compliance and elevated tissue
elastance; and (iv) a decreased production of proinflam-
matory and fibrotic cytokines such as TNFa,I L - 6a n d
TGF-b1, and an increased release of antifibrotic media-
tors including IFNg and chemokine CXCL10/IP-10.
Intratracheal instillation of bleomycin induces an
acute pneumonitis with inflammatory cells aggregating
in the pulmonary interstitium followed by aberrant
fibroproliferation and collagen production in mice [22].
Our data showed that the influx of lymphocytes, other
than macrophages and neutrophils, into lungs was con-
siderably inhibited by iloprost at day 7 following bleo-
mycin injection. These results suggest that iloprost
might exert a direct inhibition of lymphocytic infiltra-
tion. Arras and colleagues have demonstrated that B
lymphocytes are critical for lung fibrosis through the
regulation of PGE2 in mice [23]. Another study per-
formed in ovalbumin-sensitized mice indicated that ilo-
prost had a direct inhibitory effect on lung dendritic
cells, but with no effect on T helper 2 lymphocytes [15].
However, we were not able to determine in this current
study which subtype of the inflammatory cells, such
as natural killer cells and B cells, could be specifically
suppressed by iloprost after bleomycin stimulation.
Figure 3 Effect of iloprost on thickened areas of alveolar
septum, histopathological scorings and hydroxyproline content
in lung tissue. A. Using digital imaging, the thickened areas of
alveolar septum in the mice treated with Bleo (no iloprost) was
significantly increased compared to those with Bleo+iloprost at day
14. Results are expressed as mean ± SEM, n = 6-8 mice per group,
***p < 0.001. B, semi-quantitative assessment was performed on day
14 using Aschroft scoring method, a significantly higher score was
observed in the mice treated with Bleo (no iloprost) than those
treated with Bleo+iloprost. Results are expressed as mean ± SEM, n
= 5-8 mice per group, *** p < 0.001. C, the hydroxyproline content
in lung tissue was significantly higher in the mice treated with Bleo
(no iloprost) than those treated with Bleo+iloprost. Results are
expressed as mean ± SEM, n = 5-7 mice per group, * p < 0.05.
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Page 6 of 12Figure 4 Effect of iloprost on infiltration of inflammatory cells into the airways after bleomycin (Bleo) injection. The mice were injected
with 2 mg/kg of Bleo (no iloprost) or bleo+iloprost, BAL fluid was collected at days 3, 7, and 14 later. The number of inflammatory cells and
lymphocytes accumulated in airways was significantly higher in the mice treated with Bleo (no iloprost) than those treated with Bleo+iloprost (A
and B), and there was no significant difference in the number of macrophages and neutrophils in BAL fluid between the mice treated with Bleo
(no iloprost) and those treated with Bleo+iloprost (C and D). Results are expressed as mean ± SEM, n = 5-8 mice each group, ** P < 0.01.
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proinflammatory cytokines promoting infiltration of
inflammatory cells and proliferation of fibroblasts
[24,25]. We showed in this study that induction of
TNFa mRNA was markedly reduced in the mice treated
with bleomycin and iloprost over the time-course of
bleomycin-induced lung injury. A previous study
reported that PGI2 analogues including iloprost
decreased TNFa production by bone marrow-derived
dendritic cells [26], and therefore the reduced mRNA
expression of TNFa m a yr e s u l tf r o mt h i si n h i b i t o r y
effect of PGI2. IL-6 may modulate pulmonary inflamma-
tion as supported by the observation that an increased
IL-6 level in BAL fluid was associated with lung fibrosis
in human and animal models [27]. In addition, bleomy-
cin-induced lung fibrosis was significantly attenuated in
mice lacking the IL-6 gene [28]. In support of these
results, our data showed that the IL-6 level in BAL fluid
was elevated in mice 3 days after bleomycin injection;
however, such increase was markedly abrogated in
iloprost-treated mice. Our data implies that iloprost
effectively inhibited the release of IL-6 from the infil-
trated inflammatory cells at the initial stage of bleomy-
cin-induced lung injury.
TGFb1, a fibrogenic cytokine, is expressed in a variety
of cells including fibroblasts, macrophages, and epithe-
lial and endothelial cells [29,30]. Evidence from human
studies and animal models indicates that TGFb1,u p -
regulated in the process of fibrosis, plays a pivotal role
in mediating the progression of the fibrotic diseases by
stimulating fibroblasts to synthesize extracellular matrix
proteins [31,32]. Sime and colleagues demonstrated that
rats overexpressing active TGFb1 gene developed
marked lung fibrosis at day 14 [33]. Consistent with
these observations, we observed that TGFb1 mRNA and
protein was significantly inhibited in the mice treated
by iloprost+bleomycin at day 14. As represented in Fig-
ure 6, the increase in IL-6 in BAL fluid at early stage
and the elevation of TGFb1 in BAL fluid at the late
stage of bleomycin-induced pulmonary injury may sup-
port previous reports indicating that IL-6 may regulate
TGFb1 signaling [34]. Collectively, these studies indicate
that the involvement of PGI2 in preventing lung fibrosis
may be due to its direct inhibitory effect on cellular
immune response, leading to a reduction in fibrotic
mediators.
There is substantial evidence supporting a key role of
inhibitory modulators such as the Th1 cytokine, IFNg,
against fibroblast activation, [35]. A relative deficiency in
IFNg mRNA expression was associated with progressive
lung fibrosis in IPF patients [36]. Exogenous administra-
tion of IFNg has been shown to be critical for limiting
lung fibrosis in CXCR3 knockout mice lacking endogen-
ous IFNg [ 3 7 ] .A ni nv i t r os t u d yh a ss u g g e s t e dt h a t
IFNg exerts the inhibitory effect on TGFb1 signaling
pathways [38]. In this study, we reported that IFNg
levels were markedly higher in the mice treated with ilo-
prost and bleomycin than those treated with bleomycin
without iloprost. Interestingly, we first observed that ilo-
prost significantly induced production of IFNg in PBS
treated-mice by day 14 in this current study (Figure 6F),
indicating that PGI2 is capable of upregulating anti-
fibrotic mediators such as IFNg. Additionally, an in vivo
study examining the changes of biomarkers in IPF
patients indicated that IFNg may modulate fibrosis by
down-modulating several pathways relevant to fibrosis,
angiogenesis, proliferation, and immunoregulation [39].
The exact regulatory mechanism of PGI2 on IFNg needs
further investigation.
CXCL10/IP-10, which is regulated by the antifibrotic
factor IFNg, has been shown to attenuate bleomycin-
induced pulmonary fibrosis in mice via inhibition of
fibroblast recruitment or of angiogenesis [40]. CXCL10-
deficient mice displayed increased fibroblast
Figure 5 Effect of iloprost on alteration of lung mechanics
induced by bleomycin (Bleo). Measurement of lung function was
performed at 21 days after injecting 2 mg/kg of bleomycin.
Decrease in static compliance (Cst) (A) and increase in tissue
elastance (H) (B) were significantly attenuated in the mice treated
with Bleo+iloprost. Results are expressed as mean ± SEM, n = 10-12
mice per group, * P < 0.05, ** P < 0.01.
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Page 8 of 12Figure 6 Effect of iloprost on cytokines and chemokines at mRNA and protein levels. BAL fluid and lung tissue were harvested at day 14
after injection of 2 mg/kg of bleomycin (Bleo) (no iloprost) or bleo+iloprost. mRNA expression of cytokines and CXCL10 was analyzed by semi-
quantitative RT-PCR. The concentration of cytokines and CXCL 10 in BAL fluid was assayed by ELISA. Panels A-D show that mRNA expression of
TNFa, IL-6, TGFb1, and CXCL10 in lung tissue, n = 5-8 mice per group, * P < 0.05. Panels E-H show that the concentration of IL-6, IFNg, TGFb1,
and CXCL10 in BAL fluid, n = 5-9 mice per group, * P < 0.05, ** P < 0.01, ***P = 0.001.
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Page 9 of 12accumulation in the lung after bleomycin exposure.
Conversely, transgenic mice overexpressing CXCL10
were less likely to die after bleomycin exposure, asso-
ciated with a reduction in fibroblast accumulation in the
lung [41,42]. Our data demonstrated that there was an
increase in CXCL10/IP-10 mRNA level by day 7 and at
the protein level at day 14 in the mice treated with ilo-
prost and bleomycin as compared to those treated with
bleomycin (no iloprost). We cautiously propose that
induction of CXCL10/IP-10 could be secondary to the
effect of IFNg which was up-regulated by iloprost in our
investigation; however, we cannot rule out other path-
ways modulating CXCL10/IP-10 in response to
bleomycin.
An alternative explanation for both the reduced
inflammatory and fibrotic response to bleomycin by ilo-
prost in mice could be eicosanoid imbalance favoring
the overproduction of antifibrotic prostaglandins (PGE2)
and underproduction of fibrotic leukotrienes (LTB4).
PGE2 is generally recognized as a potent anti-fibrotic
agent, and is a major eicosanoid product of alveolar
epithelial cells, macrophages, and fibroblasts [43,44].
Deficiency in PGE2 has been linked to severity of lung
injury and fibrosis [23,45]. The production of PGE2 sig-
nificantly rose in BAL fluid after intratracheal instillation
of bleomycin; however, the increase seen in the mice
treated with iloprost and bleomycin was similar to those
treated with bleomycin (no iloprost) in this current
model. Lovgren and coworkers using mice lacking
COX-2 and IP demonstrated that PGE2 was not
involved in the protection against bleomycin-induced
lung fibrosis provided by prostacyclin [13]. Thus, a
PGI2-mediated mechanism of preventing lung fibrosis
induced by bleomycin is likely to be unrelated to PGE2.
Leukotriene B4 functions as a proinflammatory and pro-
fibrotic mediator by binding to its specific receptor [6].
Iloprost did not modulate the increase in LTB4 levels in
BAL fluid in response to bleomycin, suggesting that ilo-
prost may not affect the lipoxygenase pathway and that
iloprost does not limit bleomycin-induced lung pathol-
ogy by inhibition of LTB4.
In this study, iloprost given at day 7 post-bleomycin,
the time point at which pneumonitis and fibrosis are
established, failed to decrease mortality and weight loss,
to attenuate inflammation and to reverse lung fibrosis in
bleomycin-treated mice by day 21. These data may indi-
cate that iloprost can be preventive, but possibly not
therapeutic, for lung fibrotic diseases. It must be empha-
sized that iloprost was given at one single dose by intra-
peritoneal route in our study, and therefore additional
studies are necessary to test for a reversal effect of ilo-
prost in a time- and dose-dependent fashion, e.g. when
given 2-3 days after bleomycin injection and with
repeated doses. In addition, whether long-term treat-
ment with iloprost administered via the inhaled route
would be beneficial for patients with lung fibrotic dis-
eases should be further investigated.
Conclusions
In conclusion, these observations provide evidence for a
beneficial role of PGI2 in dampening pulmonary inflam-
mation and fibrosis, possibly through inhibiting recruit-
ment of inflammatory cells (predominantly lymphocytes)
and decreasing production of TNFa,I L - 6a n dT G F b1,
while promoting the generation of IFNg and IFNg-tar-
geted CXCL10/IP-10, which are anti-fibroproliferative.
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